Physician profile
David B Abrams
NPI 1881654341
$4,246.37
in general payments reported to CMS, 2019-2025
21 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $265 · 2021: $314 · 2022: $891 · 2023: $1,096 · 2024: $497 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,040.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $851.75 | 2019-2024 | |
| Glaukos Corporation | $495.99 | 2022-2025 | Idosetr |
| Alcon Vision LLC | $405.29 | 2019-2023 | Hydrus Microstent, Simbrinza |
| New World Medical,INC. | $349.26 | 2023-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Aerie Pharmaceuticals, INC. | $335.64 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $243.19 | 2024-2025 | Syfovre |
| Allergan, INC. | $219.94 | 2019-2021 | |
| Abbvie INC. | $196.89 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Sun Pharmaceutical Industries INC. | $172.90 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $149.94 | 2023 | Eylea Hd |
| Horizon Therapeutics Plc | $124.97 | 2023 | Tepezza |
| Shire North American Group INC | $121.83 | 2019 | |
| Akorn, INC. | $108.61 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $107.91 | 2025 | Envista Mx60 Iol |
| Carl Zeiss Meditec, INC. | $105.00 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $93.96 | 2019-2022 | |
| Akorn Operating Company LLC | $80.04 | 2021 | |
| Novo Nordisk INC | $24.33 | 2025 | Rybelsus, Ozempic |
| Dompe US, INC. | $23.45 | 2022 | |
| Eyevance Pharmaceuticals LLC | $19.06 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.